Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 15;11(4):169.
doi: 10.3390/diseases11040169.

The Role of Erythrocyte Sedimentation Rate (ESR) in Myeloproliferative and Lymphoproliferative Diseases: Comparison between DIESSE CUBE 30 TOUCH and Alifax Test 1

Martina Pelagalli  1   2 , Flaminia Tomassetti  1   2 , Eleonora Nicolai  1 , Alfredo Giovannelli  1   2 , Silvia Codella  1   2 , Mariannina Iozzo  2 , Renato Massoud  1   2 , Roberto Secchi  3 , Adriano Venditti  3 , Massimo Pieri  1   2 , Sergio Bernardini  1   2
Affiliations

The Role of Erythrocyte Sedimentation Rate (ESR) in Myeloproliferative and Lymphoproliferative Diseases: Comparison between DIESSE CUBE 30 TOUCH and Alifax Test 1

Martina Pelagalli et al. Diseases. .

Abstract

(1) Background: The erythrocyte sedimentation rate (ESR) is widely diffused in hematology laboratories to monitor inflammatory statuses, response to therapies (such as antibiotics), and oncologic diseases. However, ESR is not a specific diagnostic marker but needs to be contextualized and compared with clinical and other laboratory findings. This study aimed to investigate the performance of two automated instruments, namely the DIESSE CUBE 30 TOUCH (DIESSE, Siena, Italy) and the Alifax Test 1 (Alifax Srl, Polverara, Italy), in comparison with the gold standard, the Westergren method, in lymphoproliferative and myeloproliferative patients. (2) Methods: 97 EDTA samples were selected from the hematology department of Roma Tor Vergata Hospital and analyzed. Statistical analysis was applied. (3) A good correlation between CUBE 30 TOUCH and the gold standard was observed in the overall sample (R2 = 0.90), as well as in patients with lymphoproliferative diseases (R2 = 0.90) and myeloproliferative diseases (R2 = 0.90). The correlation between Test 1 and the gold standard was observed in the overall sample (R2 = 0.68), as well as in patients with lymphoproliferative diseases (R2 = 0.79) and myeloproliferative diseases (R2 = 0.53). (4) Conclusions: The CUBE 30 TOUCH appears to be a more trustworthy tool for evaluating ESR in these pathologies.

Keywords: ESR; cancer; lymphoproliferative diseases; myeloproliferative diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Passing–Bablok correlation for the overall samples between CUBE 30 TOUCH versus Westergren method. (B) Passing–Bablok correlation for the overall samples between Test 1 versus Westergren method. [Solid line: regression line; dashed lines: the confidence interval’s lines; circles: identity line (x = y)].
Figure 2
Figure 2
(A) Passing–Bablok correlation of CUBE 30 TOUCH versus Westergren method of data from the patients into lymphoproliferative diseases. (B) Passing–Bablok correlation of Test 1 versus Westergren method of data from the patients into lymphoproliferative diseases. (C) Passing–Bablok correlation of CUBE 30 TOUCH versus Westergren method of data from the patients into myeloproliferative diseases. (D) Passing–Bablok correlation of Test 1 versus Westergren method of data from the patients into myeloproliferative diseases. [Solid line: regression line; dashed lines: the confidence interval’s lines; circles: identity line (x = y)].
Figure 3
Figure 3
(A) Passing–Bablok correlation of CUBE 30 TOUCH versus Westergren method of data from patients at the onset of diseases. (B) Passing–Bablok correlation of Test 1 versus Westergren method of data from patients at the onset of diseases. (C) Passing–Bablok correlation of CUBE 30 TOUCH versus Westergren method of data from patients under pharmaceutical treatment. (D) Passing-Bablok correlation of Test 1 versus Westergren method of data from patients under pharmaceutical treatment. [Solid line: regression line; dashed lines: the confidence interval’s lines; circles: identity line (x = y)].
See this image and copyright information in PMC

References

    1. Campo E., Jaffe E.S., Cook J.R., Quintanilla-Martinez L., Swerdlow S.H., Anderson K.C., Brousset P., Cerroni L., de Leval L., Dirnhofer S., et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee. Blood. 2022;140:1229–1253. doi: 10.1182/blood.2022015851. - DOI - PMC - PubMed
    1. Chaparro C.M., Suchdev P.S. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann. N. Y. Acad. Sci. 2019;1450:15–31. doi: 10.1111/nyas.14092. - DOI - PMC - PubMed
    1. Smith M.M., Renew J.R., Nelson J.A., Barbara D.W. Red Blood Cell Disorders: Perioperative Considerations for Patients Undergoing Cardiac Surgery. J. Cardiothorac. Vasc. Anesth. 2019;33:1393–1406. doi: 10.1053/j.jvca.2018.08.001. - DOI - PubMed
    1. Lassila R. Platelet Function Tests in Bleeding Disorders. Semin. Thromb. Hemost. 2016;42:185–190. doi: 10.1055/s-0036-1571307. - DOI - PubMed
    1. Franco A.T., Corken A., Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582–588. doi: 10.1182/blood-2014-08-531582. - DOI - PMC - PubMed

LinkOut - more resources